Alessandro M.
- Country
- Italy
- Department
- Thoracopulmonary
Research Overview
- A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
- Efficacy and Safety of PF-08634404 Plus Combination Therapy Versus Pembrolizumab Plus Combination Therapy in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 400 of 641 partner sites.
Specializations
Non-Small Cell Lung Cancer Focus
Primary investigator focused on developing therapeutic strategies for advanced non-small cell lung cancer, with extensive research in both squamous and non-squamous NSCLC variants.
- Metastatic NSCLC Treatment
- Stage III Unresectable Disease
- First-line Treatment Approaches
Particular emphasis on investigating novel combination therapies and maintenance treatment strategies.
Targeted Therapy Research
Specializes in studying targeted treatments for specific genetic mutations in lung cancer, including EGFR mutations, RET fusion-positive, and KRAS G12C mutations.
- Biomarker-Driven Therapies
- Resistance Mechanisms
- Personalized Treatment Approaches
Focuses on developing precision medicine strategies for genetically defined patient populations.
Immunotherapy Innovation
Leading research in immunotherapy treatments for lung cancer, including studies of PD-L1 expression and novel immune checkpoint inhibitors.
- Combination Immunotherapy
- Maintenance Protocols
- Biomarker Development
Explores innovative immunotherapy combinations and treatment sequencing strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.